Bioerodible polyester polymer axitinib ocular implants and related methods of use

An implant comprising:

• axitinib;
• and
• a bioerodible polyester polymer blend comprising at least two polymers, wherein the bioerodible polyester polymer blend comprises an acid or ester end group polylactic acid (PLA) and an acid or ester end group poly-D,L-lactide-co-glycolide (PLGA), and wherein at least one of the two polymers comprises an ester end group,
• wherein the PLGA is selected from polymers with lactide to glycolide ratios selected from between about 50:50 to about 85:15, and wherein the PLGA is selected from polymers with an inherent viscosity selected from between about 0.16 dl/g to about 1.0 dl/g, and
• wherein the axitinib is present in the implant in an amount selected from a range of between about 5 and about 80 percent (w/w).

An implant comprising:

• axitinib, and
• a bioerodible polyster polymer blend, comprising at least two polymers, wherein the bioerodible polyester polymer blend comprises an acid or ester end group polylactic acid (PLA) and an acid or ester end group poly-D,L-lactide-co-glycolide (PLGA), and wherein at least one of the two polymers comprises an ester end group,
• wherein the ratio of PLA to PLGA is selected from a range of between about 10:1 to about 1:10, a range of between about 9:1 to about 1:9, a range of between about 8:1 to about 1:8, a range of between about 7:1 to about 1:7, a range of between about 6:1 to about 1:6, a range of between about 5:1 to about 1:5, or a range of between about 4:1 to about 1:4 and
• wherein the axitinib is present in the implant in an amount selected from a range of between about 5 and about 80 percent (w/w).

An implant comprising:

• axitinib, and
• a bioerodible polyester polymer blend,
• wherein the axitinib is present in the implant in an amount selected from a range of between about 5 and 80 percent (w/w), and
• wherein the release rate of the axitinib from the composite implant is selected from a range of between about 10 ng/day to about 10 mg/day.

An implant comprising:

• axitinib, and
• a bioerodible polyester polymer blend,
• wherein the axitinib is present in the implant in an amount selected from a range of between about 5 and 80 percent (w/w), and
• wherein a burst release of axitinib from the implant is less than 10 percent (w/w) over an initial 24-hour period from implantation in an eye of a subject.

An implant comprising:

• axitinib, and
• a bioerodible polyester polymer blend,
• wherein the axitinib is present in the implant in an amount selected from a range of between about 5 and 80 percent (w/w), and
• wherein a burst release of the axitinib from the implant is less than 1 percent (w/w) over an initial 24-hour period from implantation in an eye of a subject.

An implant comprising:

• axitinib, and
• a bioerodible polyester polymer blend,
• wherein the axitinib is present in the implant in an amount selected from a range of between about 5 and 80 percent (w/w), and
• wherein the release rate of the axitinib from the implant is substantially constant over an initial three-month period from implantation beginning with the end of the burst release or lag phase, but not more than 14 days post-implantation.

An implant comprising:

• axitinib, and
• a bioerodible polyester polymer blend,
• wherein the axitinib is present in the implant in an amount selected from a range of between about 5 and 80 percent (w/w), and
• wherein the release rate of the axitinib from the implant is near-zero order or pseudo-zero order over an initial three-month period from implantation beginning with the end of the burst release or lag phase, but not more than 14 days post-implantation.